ArticleJournal of virology2001
Feline Pit2 functions as a receptor for subgroup B feline leukemia viruses.
Article in Journal of virology, 2001. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 46 citations in OpenAlex.
- Riboflavin transporter: evidence of a role as entry receptor for chimpanzee endogenous retrovirus.Virus evolution · 2025Article
- FeLIX is a restriction factor for mammalian retrovirus infection.Journal of virology · 2024Article
- Multiple recombination events between endogenous retroviral elements and feline leukemia virus.Journal of virology · 2024Article
- Exploring the link between viruses and cancer in companion animals: a comprehensive and comparative analysis.Infectious agents and cancer · 2023Review
- Convergent evolution of antiviral machinery derived from endogenous retrovirus truncated envelope genes in multiple species.Proceedings of the National Academy of Sciences of the United States of America · 2022Article
- Article
- Feline Leukemia Virus (FeLV) Endogenous and Exogenous Recombination Events Result in Multiple FeLV-B Subtypes during Natural Infection.Journal of virology · 2021Article
- Reduced Folate Carrier: an Entry Receptor for a Novel Feline Leukemia Virus Variant.Journal of virology · 2019Article
- Feline Leukemia Virus (FeLV) Disease Outcomes in a Domestic Cat Breeding Colony: Relationship to Endogenous FeLV and Other Chronic Viral Infections.Journal of virology · 2018Article
- Transmission, Evolution, and Endogenization: Lessons Learned from Recent Retroviral Invasions.Microbiology and molecular biology reviews : MMBR · 2018Review
- A Retrospective Examination of Feline Leukemia Subgroup Characterization: Viral Interference Assays to Deep Sequencing.Viruses · 2018Review
- Novel Feline Leukemia Virus Interference Group Based on the env Gene.Journal of virology · 2016Article
- Ancestral Mutations Acquired in Refrex-1, a Restriction Factor against Feline Retroviruses, during its Cooption and Domestication.Journal of virology · 2016Article
- Disruption of thiamine uptake and growth of cells by feline leukemia virus subgroup A.Journal of virology · 2013Article
- The surface glycoprotein of a natural feline leukemia virus subgroup A variant, FeLV-945, as a determinant of disease outcome.Veterinary immunology and immunopathology · 2011Article
- Immunodeficiencies caused by infectious diseases.The Veterinary clinics of North America. Small animal practice · 2010Review
- Feline leukemia virus T entry is dependent on both expression levels and specific interactions between cofactor and receptor.Virology · 2007Article
- A putative thiamine transport protein is a receptor for feline leukemia virus subgroup A.Journal of virology · 2006Article
- Envelope determinants for dual-receptor specificity in feline leukemia virus subgroup A and T variants.Journal of virology · 2006Article
- Probing sequence variation in the receptor-targeting domain of feline leukemia virus envelope proteins with peptide display libraries.Journal of virology · 2005Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 4 institutions in 3 countries.
Funding
Abstract
Different subgroups of feline leukemia virus (FeLV) use different host cell receptors for entry. Subgroup A FeLV (FeLV-A) is the virus that is transmitted from cat to cat, suggesting that cells expressing the FeLV-A receptor are important targets at the earliest stages of infection. FeLV-B evolves from FeLV-A in the infected cat through acquisition of cellular sequences that are related to the FeLV envelope gene. FeLV-Bs have been shown to infect cells using the Pit1 receptor, and some variants can infect cells at a lower efficiency using Pit2. Because these observations were made using receptor proteins of human or rodent origin, the role that Pit1 and Pit2 may play in FeLV-B replication in the cat is unclear. In this study, the feline Pit receptors were cloned and tested for their ability to act as receptors for different FeLV-Bs. Some FeLV-Bs infected cells expressing feline Pit2 and feline Pit1 with equal high efficiency. Variable region A (VRA) in the putative receptor-binding domain (RBD) was a critical determinant for both feline Pit1 and feline Pit2 binding, although other domains in the RBD appear to influence how efficiently the FeLV-B surface unit can bind to feline Pit2 and promote entry via this receptor. An arginine residue at position 73 in VRA was found to be important for envelope binding to feline Pit2 but not feline Pit1. Interestingly, this arginine is not found in endogenous FeLV sequences or in recombinant viruses recovered from feline cells infected with FeLV-A. Thus, while FeLV-Bs that are able to use feline Pit2 can evolve by recombination with endogenous sequences, a subsequent point mutation during reverse transcription may be needed to generate a virus that can efficiently enter the cells using the feline Pit2 as its receptor. These studies suggest that cells expressing the feline Pit2 protein are likely to be targets for FeLV-B infection in the cat.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.